Two medical device companies have announced a transaction that could shake up the U.S. electrophysiology market. 

This care model has grown in popularity, with startups such as Prenuvo and Ezra charging $2,500 out of pocket to screen asymptomatic patients for cancer and other diseases

“These findings suggest that changing the genetic testing paradigm to population-based testing could prevent thousands of breast and ovarian cancers," experts wrote in JAMA. 

ACR noted that Congress is returning from its August recess, with one of the “most critical” considerations pertaining to government funding for fiscal 2025. 

In a letter to Congress, the groups are urging lawmakers to support HR 9001 and lift the ban on physician-run hospitals.

Due to a risk of fatal overdose, the recall is labeled as the most serious of its type. While no patients have died, two have reportedly been injured. 

The new device, already cleared by the FDA, was designed to treat femoropopliteal and below-the-knee PAD. 

LBBAP is a relatively new alternative to biventricular pacing. The FDA's decision was based largely on data from the BIO-CONDUCT clinical trial.